


## (Rac)-Reparixin

|                           |                                                   |       |          |
|---------------------------|---------------------------------------------------|-------|----------|
| <b>Cat. No.:</b>          | HY-15251A                                         |       |          |
| <b>CAS No.:</b>           | 957407-64-6                                       |       |          |
| <b>Molecular Formula:</b> | C <sub>14</sub> H <sub>21</sub> NO <sub>3</sub> S |       |          |
| <b>Molecular Weight:</b>  | 283.39                                            |       |          |
| <b>Target:</b>            | Others                                            |       |          |
| <b>Pathway:</b>           | Others                                            |       |          |
| <b>Storage:</b>           | Powder                                            | -20°C | 3 years  |
|                           |                                                   | 4°C   | 2 years  |
|                           | In solvent                                        | -80°C | 6 months |
|                           |                                                   | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (352.87 mM)  
 \* "≥" means soluble, but saturation unknown.

| Concentration | Mass      |            |            |
|---------------|-----------|------------|------------|
|               | 1 mg      | 5 mg       | 10 mg      |
| <b>1 mM</b>   | 3.5287 mL | 17.6435 mL | 35.2871 mL |
| <b>5 mM</b>   | 0.7057 mL | 3.5287 mL  | 7.0574 mL  |
| <b>10 mM</b>  | 0.3529 mL | 1.7644 mL  | 3.5287 mL  |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(Rac)-Reparixin is the inactive isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC<sub>50</sub>s of 1 and 100 nM, respectively.

### REFERENCES

- [1]. Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. *Clinics (Sao Paulo)*. 2013;68(3):391-4.
- [2]. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. *Proc Natl Acad Sci U S A*. 2004 Aug 10;101(32):11791-6.
- [3]. Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. *Ann Rheum Dis*. 2016 Apr;75(4):721-9.

- 
- [4]. Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. *J Immunol.* 2018 Jul 15;201(2):814-820.
- [5]. Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. *J Med Chem.* 2007 Aug 23;50(17):3984-4002.
- [6]. Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. *Br J Pharmacol.* 2012 Jan;165(2):436-54.
- [7]. Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. *Biol Pharm Bull.* 2011;34(1):120-7.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA